Effect of intratumoral application of methotrexate in vivo on frequency of micronuclei in peripheral blood lymphocytes

Archive of Oncology

Volumn 11, Issue 1, 2003, Pages 1-4

  Novaković, Tanja ^a   Milosevic Dordevic, Olivera ^b,d   Grujičić, Darko ^b   Marinković, Dragoslav ^c   Janković, Slobodan ^a   Arsenijević, Slobodan ^a  

^a Clinic of Gynecology Obstetrics   (Serbia)

^b Faculty of Science   (Serbia)

^c Faculty of Biology   (Serbia)

^d UNIVERSITY OF KRAGUJEVAC   (Serbia)

Author keywords

Injections, Intralesional; Lymphocytes; Methotrexate; Micronuclei; Myoma; Uterine Neoplasms

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; METHOTREXATE;

ADULT; ARTICLE; CLINICAL ARTICLE; CYTOKINESIS; DRUG MECHANISM; FEMALE; GENOTOXICITY; HUMAN; HUMAN CELL; LYMPHOCYTE; MICRONUCLEUS; MUTAGENICITY; TREATMENT OUTCOME; UTERUS MYOMA; UTERUS TUMOR;

EID: 0038690534     PISSN: 03547310     EISSN: None     Source Type: Journal    
DOI: 10.2298/AOO0301001N     Document Type: Article

References (22)

1. Brkić M. Local application of methotrexate in the therapy of myoma uteri (magistarski rad). Kragujevac: University in Kragujevac; 2000. p. 1-73.
2. Fenech M, Morley AA. Measurement of micronuclei in lymphocytes. Mutat Res 1985;147:29-36.
3. Fenech M, Morley AA. Kinetochore detection in micronuclei: an alternative method for measuring chromosome loss. Mutagenesis 1989;4:98-104.
4. Joksić G. Comparative investigations of the chromosome aberration and micronuclei frequency in human peripheral lymphocytes in the cases of internal contamination by radionuclides (disertation). Belgrade: University in Belgrade; 1990. p. 1-115.
5. Edwards JH. Chromosome analysis from capillary blood. Cytogenetics 1962;1:90-6.
6. Frland A. A micromethod for chromosome analysis on peripheral blood-cultures. Lancet 1962;2:1281-2.
7. Fenech M. The advantages and disandvantages of the cytokinesis-block micronucleus method. Mutat Res 1997;392:11-8.
8. Shanin AA, Ismail MM, Saleh AM, Moustafa HA, Aboul-Ella AA, Gabr HM. Protective effect of folic acid on low-dose methotrexate genotoxicity. Z Reumatology 2001;60(2):63-8.
9. Acar H, Caliskan U, Demirel S, Largaespada DA. Micronucleus incidence and their chromosomal origin related to therapy in acute lymphoblastic leukemia (ALL) patients: detection by micronucleus and FISH techniques. Teratog Carcinog Mutagen 2001;21(5):341-7.
10. Kasahara Y, Nakai Y, Miura D, Yagy K, Hirabayashi K, Makita TT. Mechanism of induction of micronuclei and chromosome aberrations in mouse bone marrow by multiple treatments of methotrexate. Mutat Res 1992;280:117-28.
11. Allegra CJ, Fine RL, Darke JC, Chabner BA. The effect of methotrexate on intracellular folate pools in human MCF-7 breast cancer cells: evidence for direct inhibitions of purine synthesis. J Biol Chem 1986;261:6478-85.
12. Warlick CA, Sweeney CL, Mc Ivor RS. Maintenance of differential methotrexate toxicity between cells expressing drug resistant and wild-type dihydrofolate reductase activities in the presence of nucleosides through nucleoside transport inhibition. Biochem Pharmacol 2000;59(2):141-51.
13. Chu E, Allegra CJ. Antifolates. In: Chabner BA, Longo DL, editors. Cancer Chemotherapy and Biotherapy: Principles and Practise. Philadelphia: Lippincott; 1996. p. 109-48.
14. Bystroff C, Kraut J. Crystal structure of unliganded Escherichia coli dihydrofolate reductase. Lingand-induced conformational changes and cooperativity in binding. Biochemistry 1991;30:2227-39.
15. Saritha TB, Ahuja RZ. Inter-individual variation in chromosome aberration response to treatment with aphidicolin and folate deficiency. Med Sci Res 1990;18:785-7.
16. Miloševič-Dordević O, Marinkovid D, Arsenijevid S. Genetic determination of sister-chromatid exchange variation in nonstimulated human lymphocytes after treatment with cytostatics in vitro. Genetika 1996; 28(3): 185-92.
17. Di Giorgio C, De Meo MP, Laget M, Guirand H, Botta A, Dumenil G. The micronucleus assay in human lymphocytes: screening for inter-individual variability and application to biomonitoring. Carcinogenesis 1994; 15: 313-7.
18. Trippet T, Schlemmer S, Elisseyeff Y, Goker E, Wachter M, Steinherz P et al. Defective transport as a mechanism of acquired resistance to methotrexate in patients with acute lymphoblastic leukemia. Blood 1992; 80: 1158-62.
19. Martherly LH, Taub JW, Wong SC, Simpson PM, Ekizian R, Buck S et al. Increased frequency of expression of elevated dihydrofolate reductase in T-cell versus B-precursor acute lymphoblastic leukemia in children. Blood 1997; 90: 578-89.
20. Li WW, Lin JT, Schweitzer BI, Tong WP, Niedzwiecki D, Bertino JR. Intrinsic resistance to methotrexate in human soft tissue sarcoma cell lines. Cancer Res 1992; 52: 3908-13.
21. Giuseppe SA, Longo S, Joseph RB. Current understanding of methotrexate pharmacology and efficacy in acute leukemias. Use a newer antifolates in clinical trials. Hematologia 2001;86:121-7.
22. Chu E, Takimoto CH, Voeller D, Grem JL, Allegra CJ. Specific binding of human dihydrofolate reductase protein to dihydrofolate reductase messenger RNA in vitro. Biochemistry 1993;32:4756-60.